



CCSS

The Collaborative for
Cannabinoid Science & Safety

CCSS Supports the Dietary Supplement Listing Act of 2022

CONTACT

Libby Baney

Libby.Baney@FaegreDrinker.com

(202) 312 - 7438

FOR IMMEDIATE RELEASE

May 18, 2022

WASHINGTON, DC – The [Collaborative for Cannabinoid Science & Safety \(CCSS\)](https://www.ccss-collaborative.org/) applauds Sen. Durbin (D-IL) and Sen. Braun (R-IN) for their efforts to protect public health through introduction of the bipartisan S. 4090 Dietary Supplement Listing Act of 2022. If enacted, this would require dietary supplement manufacturers to list their products with the Food Drug Administration (FDA). Product registration would be an important component of any regulatory regime for cannabinoids in dietary supplements. This new authority will provide FDA a tool to protect consumers from cannabinoids products marketed with false and misleading claims that they can diagnose, cure, mitigate, treat, or prevent diseases, and those that are poorly manufactured, incorrectly labeled, deliver high levels of THC or other adulterants, and have avoided premarket safety evaluation and review.

This bill represents an important step forward in efforts to address risks to public health from the proliferation of cannabinoid-containing products marketed with false and misleading claims that they can diagnose, cure, mitigate, treat, or prevent diseases. Currently, FDA does not have the authority to require the listing of all marketed dietary supplements in a product registry. This limits the agency's ability to identify, track and enforce regulatory requirements in the supplement marketplace.

Each day, consumers are put at risk from CBD products marketed as dietary supplements that are poorly manufactured, incorrectly labeled, deliver high levels of THC or other adulterants, and have avoided premarket safety evaluation and review. CCSS supports this critical legislation and thanks Senators Durbin and Braun for taking much needed action to protect consumers.

About the Collaborative for Cannabinoid Science and Safety

The Collaborative for Cannabinoid Science & Safety (CCSS) provides a forum for stakeholders to exchange information, build alliances around shared interests and priorities, and respond to policies and practices affecting cannabidiol research, safety and quality. The overarching goal of CCSS is to foster dialogue and cooperation among a diverse group of stakeholders interested in encouraging scientifically-based research into the therapeutic potential of cannabinoids and ensuring the quality and safety of cannabinoids and cannabinoid-containing products available for consumer use. For more information, visit <https://www.ccss-collaborative.org/>.